Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The FREEDOM studies evaluated exenatide delivered via an implanted minipump in patients with type 2 diabetes; the final study evaluated cardiovascular outcomes but offers up more questions than answers.
AI-based models may amplify pre-existing human bias within datasets; addressing this problem will require a fundamental realignment of the culture of software development.
mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study takes the first step toward this goal.
Two early-phase clinical trials show impressive response rates and symptom improvement with the selective KIT inhibitor avapritinib, which will provide a much-needed new treatment option for patients.
New research can help policymakers make evidence-based decisions about the risks and benefits of in-person schooling; strategic use of the available data will be key to getting this right.
New studies highlight the immunological benefits of COVID-19 vaccine boosters, but questions remain over how to best make use of a limited global supply.
SGLT-2 inhibitors show promise for treatment of heart failure with preserved ejection fraction, but clinical data are nuanced. Appropriate endpoint selection will be key to deciphering their benefits.
A translational study reveals a role for interleukin-1–fibroblast–neutrophil signaling in drug-resistant inflammatory bowel disease, opening a potential path to targeted treatment.
A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.
New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.
A new spatial analysis calls for a tiered and geographically targeted approach to tackling the vast, ongoing burden of anemia in women within low- and middle-income countries.
A phase 1 trial shows the feasibility of a novel approach combining a powered hip exoskeleton with a passive leg prosthesis to improve the energy efficiency of walking.
Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.
Machine learning applied to electronic medical records can be used to create personalized lab-test reference ranges and to quantify disease risk, which will pave the way for precision medicine in clinical care.
Cytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of respiratory failure, but timing and patient selection are key.
The first preliminary evidence that in vivo gene editing in a clinical setting is feasible with no early signs of severe adverse events comes from an ongoing clinical trial to treat transthyretin amyloidosis, a fatal monogenetic disease.
Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.
A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.
Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.
